Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in vascular smooth muscle cells

Toshihiro Ichiki, Kotaro Takeda, Tomotake Tokunou, Naoko Iino, Kensuke Egashira, Hiroaki Shimokawa, Katsuya Hirano, Hideo Kanaide, Akira Takeshita

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, so-called statins, reduce the relative risk of a major coronary event by lowering the serum cholesterol level. In addition, statins may confer beneficial effects by cholesterol-lowering independent mechanisms, which are incompletely characterized. Because angiotensin II (Ang II) plays crucial roles in the pathogenesis of cardiovascular diseases, we examined the effect of statins on the expression of the Ang II type 1 receptor (AT1-R) in cultured vascular smooth muscle cells (VSMCs). Cerivastatin and fluvastatin reduced the AT1-R mRNA and the AT1-R protein levels; however, pravastatin lacked this effect. Cerivastatin and fluvastatin suppressed the AT1-R promoter activity measured by luciferase assay but did not affect AT1-R mRNA stability, suggesting that the suppression occurs at the transcriptional level. Coincubation of VSMCs with mevalonate or geranylgeranyl pyrophosphate but not with farnesyl pyrophosphate reversed the cerivastatin-induced AT1-R downregulation. Overexpression of dominant-negative Rho A also suppressed AT1-R mRNA expression. Treatment with cerivastatin for 24 hours reduced the calcium response of VSMCs to Ang II. Taken together, statins downregulate AT1-R expression through a mevalonate-dependent, geranylgeranyl pyrophosphate-dependent, and Rho A-dependent manner and attenuate the biological function of Ang II. Downregulation of AT1-R may contribute to the cholesterol-independent beneficial effect of statins on the cardiovascular system.

Original languageEnglish
Pages (from-to)1896-1901
Number of pages6
JournalArteriosclerosis, thrombosis, and vascular biology
Volume21
Issue number12
DOIs
Publication statusPublished - Jan 1 2001

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Angiotensin Type 1 Receptor
Coenzymes
Vascular Smooth Muscle
fluvastatin
Smooth Muscle Myocytes
Oxidoreductases
Down-Regulation
Angiotensin II
Cholesterol
Pravastatin
Mevalonic Acid
Messenger RNA
RNA Stability
Cardiovascular System
Luciferases
Cardiovascular Diseases
Calcium
cerivastatin
Serum

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in vascular smooth muscle cells. / Ichiki, Toshihiro; Takeda, Kotaro; Tokunou, Tomotake; Iino, Naoko; Egashira, Kensuke; Shimokawa, Hiroaki; Hirano, Katsuya; Kanaide, Hideo; Takeshita, Akira.

In: Arteriosclerosis, thrombosis, and vascular biology, Vol. 21, No. 12, 01.01.2001, p. 1896-1901.

Research output: Contribution to journalArticle

Ichiki, Toshihiro ; Takeda, Kotaro ; Tokunou, Tomotake ; Iino, Naoko ; Egashira, Kensuke ; Shimokawa, Hiroaki ; Hirano, Katsuya ; Kanaide, Hideo ; Takeshita, Akira. / Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in vascular smooth muscle cells. In: Arteriosclerosis, thrombosis, and vascular biology. 2001 ; Vol. 21, No. 12. pp. 1896-1901.
@article{ce5e16311c35462cb51bb77f6734b07a,
title = "Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in vascular smooth muscle cells",
abstract = "3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, so-called statins, reduce the relative risk of a major coronary event by lowering the serum cholesterol level. In addition, statins may confer beneficial effects by cholesterol-lowering independent mechanisms, which are incompletely characterized. Because angiotensin II (Ang II) plays crucial roles in the pathogenesis of cardiovascular diseases, we examined the effect of statins on the expression of the Ang II type 1 receptor (AT1-R) in cultured vascular smooth muscle cells (VSMCs). Cerivastatin and fluvastatin reduced the AT1-R mRNA and the AT1-R protein levels; however, pravastatin lacked this effect. Cerivastatin and fluvastatin suppressed the AT1-R promoter activity measured by luciferase assay but did not affect AT1-R mRNA stability, suggesting that the suppression occurs at the transcriptional level. Coincubation of VSMCs with mevalonate or geranylgeranyl pyrophosphate but not with farnesyl pyrophosphate reversed the cerivastatin-induced AT1-R downregulation. Overexpression of dominant-negative Rho A also suppressed AT1-R mRNA expression. Treatment with cerivastatin for 24 hours reduced the calcium response of VSMCs to Ang II. Taken together, statins downregulate AT1-R expression through a mevalonate-dependent, geranylgeranyl pyrophosphate-dependent, and Rho A-dependent manner and attenuate the biological function of Ang II. Downregulation of AT1-R may contribute to the cholesterol-independent beneficial effect of statins on the cardiovascular system.",
author = "Toshihiro Ichiki and Kotaro Takeda and Tomotake Tokunou and Naoko Iino and Kensuke Egashira and Hiroaki Shimokawa and Katsuya Hirano and Hideo Kanaide and Akira Takeshita",
year = "2001",
month = "1",
day = "1",
doi = "10.1161/hq1201.099430",
language = "English",
volume = "21",
pages = "1896--1901",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in vascular smooth muscle cells

AU - Ichiki, Toshihiro

AU - Takeda, Kotaro

AU - Tokunou, Tomotake

AU - Iino, Naoko

AU - Egashira, Kensuke

AU - Shimokawa, Hiroaki

AU - Hirano, Katsuya

AU - Kanaide, Hideo

AU - Takeshita, Akira

PY - 2001/1/1

Y1 - 2001/1/1

N2 - 3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, so-called statins, reduce the relative risk of a major coronary event by lowering the serum cholesterol level. In addition, statins may confer beneficial effects by cholesterol-lowering independent mechanisms, which are incompletely characterized. Because angiotensin II (Ang II) plays crucial roles in the pathogenesis of cardiovascular diseases, we examined the effect of statins on the expression of the Ang II type 1 receptor (AT1-R) in cultured vascular smooth muscle cells (VSMCs). Cerivastatin and fluvastatin reduced the AT1-R mRNA and the AT1-R protein levels; however, pravastatin lacked this effect. Cerivastatin and fluvastatin suppressed the AT1-R promoter activity measured by luciferase assay but did not affect AT1-R mRNA stability, suggesting that the suppression occurs at the transcriptional level. Coincubation of VSMCs with mevalonate or geranylgeranyl pyrophosphate but not with farnesyl pyrophosphate reversed the cerivastatin-induced AT1-R downregulation. Overexpression of dominant-negative Rho A also suppressed AT1-R mRNA expression. Treatment with cerivastatin for 24 hours reduced the calcium response of VSMCs to Ang II. Taken together, statins downregulate AT1-R expression through a mevalonate-dependent, geranylgeranyl pyrophosphate-dependent, and Rho A-dependent manner and attenuate the biological function of Ang II. Downregulation of AT1-R may contribute to the cholesterol-independent beneficial effect of statins on the cardiovascular system.

AB - 3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, so-called statins, reduce the relative risk of a major coronary event by lowering the serum cholesterol level. In addition, statins may confer beneficial effects by cholesterol-lowering independent mechanisms, which are incompletely characterized. Because angiotensin II (Ang II) plays crucial roles in the pathogenesis of cardiovascular diseases, we examined the effect of statins on the expression of the Ang II type 1 receptor (AT1-R) in cultured vascular smooth muscle cells (VSMCs). Cerivastatin and fluvastatin reduced the AT1-R mRNA and the AT1-R protein levels; however, pravastatin lacked this effect. Cerivastatin and fluvastatin suppressed the AT1-R promoter activity measured by luciferase assay but did not affect AT1-R mRNA stability, suggesting that the suppression occurs at the transcriptional level. Coincubation of VSMCs with mevalonate or geranylgeranyl pyrophosphate but not with farnesyl pyrophosphate reversed the cerivastatin-induced AT1-R downregulation. Overexpression of dominant-negative Rho A also suppressed AT1-R mRNA expression. Treatment with cerivastatin for 24 hours reduced the calcium response of VSMCs to Ang II. Taken together, statins downregulate AT1-R expression through a mevalonate-dependent, geranylgeranyl pyrophosphate-dependent, and Rho A-dependent manner and attenuate the biological function of Ang II. Downregulation of AT1-R may contribute to the cholesterol-independent beneficial effect of statins on the cardiovascular system.

UR - http://www.scopus.com/inward/record.url?scp=0035571607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035571607&partnerID=8YFLogxK

U2 - 10.1161/hq1201.099430

DO - 10.1161/hq1201.099430

M3 - Article

C2 - 11742861

AN - SCOPUS:0035571607

VL - 21

SP - 1896

EP - 1901

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 12

ER -